Status:
COMPLETED
Deanxit and Rivotril in Tinnitus Patients
Lead Sponsor:
University Hospital, Antwerp
Conditions:
Tinnitus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether increased tinnitus reduction can be obtained with Deanxit in patients already receiving Rivotril.
Eligibility Criteria
Inclusion
- pure tone, narrow band noise or polyphonic tinnitus
- unilateral or bilateral tinnitus
- VAS ≥ 4
- cochleair origin tinnitus
- tinnitus present 3 months or more
- age 18y or more
- intake Rivotril 1mg/d
- patient 'able to cooperate'
- patient able to fill in TQ en VAS
- No pontine angle pathology on MRI
Exclusion
- pulsatile tinnitus
- pregnancy or breast feeding
- contra-indications Deanxit
- recovery myocard infarct
- conduction disorder His
- untreated glaucoma
- MAO inhibitors: 15d stop
- otosclerosis
- middle ear pathologies
- Ménière
- somatic tinnitus
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00841230
Start Date
February 1 2009
End Date
July 1 2009
Last Update
August 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Antwerp University Hospital
Antwerp, Antwerp, Belgium, 2650